This is a routine conference participation announcement with no material new information. Monitor for any clinical data updates or financing news that may emerge from the conference. The Phase 3 trial initiation timeline (H2 2026) is unchanged and remains the key catalyst to watch.
Price Chart
Executive Summary
OKYO Pharma filed a 6-K announcing its participation in the BTIG Biotechnology Conference 2026, a virtual event on July 28-29, 2026. The filing is a routine conference participation announcement with no new financial data, clinical results, or material corporate developments. The press release reiterates the company's plan to initiate a global Phase 3 pivotal trial for urcosimod in neuropathic corneal pain in the second half of 2026.
Key Facts
- OKYO Pharma will participate in the BTIG Biotechnology Conference 2026 on July 28-29, 2026.
- The conference is virtual; management will hold 1:1 meetings.
- The company reiterates its plan to initiate a global Phase 3 pivotal trial for urcosimod in NCP in H2 2026.
- No new financial data, clinical results, or material agreements were disclosed.
Financial Impact
No financial impact disclosed.
Risk Factors
- No new material information; stock may trade on general biotech sentiment.
- Conference participation alone does not constitute a catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-034686 |
| Exhibit: ex99-1.htm | 0001493152-26-034686 |
| Document: 0001493152-26-034686-index-headers.html | 0001493152-26-034686 |
| Document: 0001493152-26-034686-index.html | 0001493152-26-034686 |
| Document: 0001493152-26-034686.txt | 0001493152-26-034686 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers